As of 2025-07-11, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -4.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 61.42 mil USD. OCX's TTM EBITDA according to its financial statements is -14.41 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.2x - 13.5x | 13.1x |
| Forward P/E multiples | 17.3x - 32.6x | 20.8x |
| Fair Price | (7.68) - (5.73) | (7.49) |
| Upside | -339.9% - -279.1% | -334.1% |
| Date | EV/EBITDA |
| 2025-07-09 | -3.80 |
| 2025-07-08 | -3.69 |
| 2025-07-07 | -3.92 |
| 2025-07-03 | -3.57 |
| 2025-07-02 | -3.94 |
| 2025-07-01 | -3.94 |
| 2025-06-30 | -3.90 |
| 2025-06-27 | -4.26 |
| 2025-06-26 | -4.60 |
| 2025-06-25 | -4.53 |
| 2025-06-24 | -4.76 |
| 2025-06-23 | -5.17 |
| 2025-06-20 | -6.32 |
| 2025-06-18 | -4.18 |
| 2025-06-17 | -4.26 |
| 2025-06-16 | -3.33 |
| 2025-06-13 | -3.17 |
| 2025-06-12 | -3.27 |
| 2025-06-11 | -3.15 |
| 2025-06-10 | -3.38 |
| 2025-06-09 | -3.43 |
| 2025-06-06 | -3.80 |
| 2025-06-05 | -3.80 |
| 2025-06-04 | -3.73 |
| 2025-06-03 | -4.00 |
| 2025-06-02 | -4.24 |
| 2025-05-30 | -4.50 |
| 2025-05-29 | -4.38 |
| 2025-05-28 | -4.52 |
| 2025-05-27 | -4.36 |
| 2025-05-23 | -4.60 |
| 2025-05-22 | -4.74 |
| 2025-05-21 | -4.00 |
| 2025-05-20 | -3.75 |
| 2025-05-19 | -3.47 |
| 2025-05-16 | -3.45 |
| 2025-05-15 | -3.45 |
| 2025-05-14 | -3.07 |
| 2025-05-13 | -3.41 |
| 2025-05-12 | -3.49 |
| 2025-05-09 | -3.61 |
| 2025-05-08 | -3.55 |
| 2025-05-07 | -3.53 |
| 2025-05-06 | -3.65 |
| 2025-05-05 | -3.71 |
| 2025-05-02 | -3.91 |
| 2025-05-01 | -4.06 |
| 2025-04-30 | -4.02 |
| 2025-04-29 | -4.10 |
| 2025-04-28 | -4.30 |